Accutar Biotech has terminated the phase 1 clinical study (NCT05489679/CTR20221967, due to strategy adjustment) of AC682 (AC0682), an orally administrated ERα-PROTAC, in ER-positive breast cancer, with 6 patients enrolled. The trial, which commenced in November 2021 in the United States, is currently active but not recruiting.
Alongside AC0682, Accutar has initiated the clinical trial for another ER degrader, AC699, which is currently ongoing. AC682 is positioned as a potential best-in-class, while AC699 is positioned as having the potential to be the best-in-class with broad mutant coverage. The trial of AC699 was initiated exclusively in the United States in December 2022.
| Accutar Pipeline |
In April 2022, the IND application of AC682 was cleared by China CDE. Accutar promptly initiated the trial, and the first patient was enrolled in October.
"In the preclinical studies, AC0682 demonstrated potent and selective ERα protein degradation with favorable pharmacological properties, as well as promising anti-tumor activity in ER-positive animal tumor models."
| Structures |
The phase 1 trial of HRS-1358, developed by Hengrui, commenced in November 2022. Currently, no data has been reported.
Comments